PMID- 34403532
OWN - NLM
STAT- MEDLINE
DCOM- 20220124
LR  - 20220124
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 35
IP  - 9
DP  - 2021 Sep
TI  - AC016405.3 functions as an oncogenic long non-coding RNA by regulating ERBB3 via 
      sponging miR-22-3p in breast cancer.
PG  - e23952
LID - 10.1002/jcla.23952 [doi]
LID - e23952
AB  - BACKGROUND: Increasing studies reported that long non-coding RNAs are involved in 
      regulating breast cancer (BRCA) progression. However, the specific roles and 
      mechanisms of lncRNAs in BRCA remain largely unknown. Here, we sought to explore 
      the functions and mechanisms of AC016405.3 in BRCA progression. METHODS: 
      Bioinformatic analysis for AC016405.3, miR-22-3p, and ERBB3 were performed on 
      starBase. The expressions of AC016405.3, miR-22-3p, and ERBB3 were examined by 
      RT-qPCR. The functions of AC016405.3 on the proliferation, migration, and 
      invasion of cells were evaluated by conducting CCK-8, colony formation, 
      wound-healing, and Transwell assays. The subcellular distribution of AC016405.3 
      in BRCA cells was identified by performing fluorescence in situ hybridization 
      (FISH) and subcellular fractionation techniques. Dual-luciferase assay was 
      applied to validate the interactions of miR-22-3p with AC016405.3 or ERBB3. The 
      interaction between ERBB3 and miR-22-3p was also tested by Anti-Ago2 RNA 
      immunoprecipitation (RIP) assay. RESULTS: The results showed that AC016405.3 is 
      highly expressed in BRCA tissues as well as cells and positively correlated with 
      poor prognosis in BRCA patients. Silencing AC016405.3 obviously repressed the 
      malignant behaviors of BRCA cells. Mechanistically, AC016405.3 functioned as a 
      competing endogenous RNA (ceRNA) for miR-22-3p in the cytoplasm and sponged 
      miR-22-3p to release its suppression of ERBB3. Rescue experiments revealed that 
      the suppression role induced by AC016405.3 depletion on malignant behaviors of 
      BRCA cells could be obviously counter by inhibiting miR-22-3p or overexpressing 
      ERBB3. CONCLUSION: AC016405.3 promotes BRCA progression by the derepression of 
      ERBB3 via sponging miR-22-3p, which may represent a potential target for BRCA 
      treatment.
CI  - (c) 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Wei, Min
AU  - Wei M
AD  - Department of Breast, School of Medicine, The International Peace Maternity and 
      Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China.
AD  - Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Breast, School of Medicine, The International Peace Maternity and 
      Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China.
AD  - Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - He, Qi
AU  - He Q
AD  - Department of Breast, School of Medicine, The International Peace Maternity and 
      Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China.
AD  - Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - Liu, Lei
AU  - Liu L
AD  - Department of Surgery, The Affiliated Tumor Hospital of Nantong University, 
      Nantong, China.
FAU - Wang, Zhiwei
AU  - Wang Z
AUID- ORCID: 0000-0001-8728-1543
AD  - Department of Breast, School of Medicine, The International Peace Maternity and 
      Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China.
AD  - Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
LA  - eng
GR  - 124119a4801/Shanghai Committee of Science and Technology, China/
GR  - Shanghai Committee of Science and Technology, China/
GR  - 81101847/Natural Science Foundation of China/
GR  - 20110073120089/Ministry of Education of China/
PT  - Journal Article
DEP - 20210817
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
SB  - IM
MH  - *Breast Neoplasms
MH  - Female
MH  - Humans
PMC - PMC8418490
OTO - NOTNLM
OT  - AC016405.3
OT  - ERBB3
OT  - breast cancer
OT  - competing endogenous RNA network
OT  - miR-22-3p
COIS- The authors declare that they have no competing interests.
EDAT- 2021/08/18 06:00
MHDA- 2022/01/27 06:00
PMCR- 2021/08/17
CRDT- 2021/08/17 17:21
PHST- 2021/07/28 00:00 [revised]
PHST- 2021/05/19 00:00 [received]
PHST- 2021/07/31 00:00 [accepted]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/08/17 17:21 [entrez]
PHST- 2021/08/17 00:00 [pmc-release]
AID - JCLA23952 [pii]
AID - 10.1002/jcla.23952 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2021 Sep;35(9):e23952. doi: 10.1002/jcla.23952. Epub 2021 Aug 
      17.